CLINICAL TRIALS PROFILE FOR PAZOPANIB HYDROCHLORIDE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Pazopanib Hydrochloride
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT02810756 ↗ | Study With Improved Solubility Pazopanib | Completed | The Netherlands Cancer Institute | Early Phase 1 | 2016-09-15 | The pharmacokinetics of a new formulation with Pazopanib will be studied. This will be done in a patient cohort of n = 12. |
| New Combination | NCT03571438 ↗ | Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors | Recruiting | University Hospital, Grenoble | N/A | 2017-10-16 | The investigators objective is to test the combination directly on organotypic cultures of tumors from patients after their excision in the Department of Urology and Renal Transplantation of the University Hospital of Grenoble and to compare their efficacy with that of currently selected treatments in the clinic. The population targeted by the combination for use in clinical practice is patients with metastatic clear cell renal cell carcinoma. Current treatments for these patients are Sunitinib, Pazopanib and Temsirolimus. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Pazopanib Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00244764 ↗ | GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma | Completed | GlaxoSmithKline | Phase 2 | 2005-10-01 | Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell Carcinoma (RCC). After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib. |
| NCT00256880 ↗ | Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma | Completed | GlaxoSmithKline | Phase 2 | 2005-01-01 | The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing. A patient may continue to receive the treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment. During the treatment phase, the patients will undergo regular assessments for safety and clinical response. |
| NCT00297258 ↗ | Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma | Completed | GlaxoSmithKline | Phase 2 | 2005-11-01 | The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists and to characterize the pharmacokinetics of pazopanib in this subject population. |
| NCT00334282 ↗ | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | Completed | GlaxoSmithKline | Phase 3 | 2006-04-01 | To evaluate efficacy and safety of pazopanib compared to placebo in patients with locally advanced and/ or metastatic renal cell carcinoma (RCC). Approximately 350-400 eligible patients will be stratified and randomized in a 2:1 ratio to receive either 800 mg pazopanib once daily or matching placebo. The study treatment will continue until patients experience disease progression, unacceptable toxicity or death. Primary objective of the study is to evaluate and compare the two treatment arms for progression-free survival. Principal secondary objective is to evaluate and compare the two treatment arms with respect to overall survival. Other objectives are overall response rate [complete response (CR) + partial response (PR)], rate of CR + PR + 6 months stable disease, and the incidence, severity and causality of adverse events and serious adverse events. Safety and efficacy assessments will be regularly performed on all patients. An Independent Data Monitoring Committee will be established to monitor safety during the course of the study and to evaluate interim efficacy data on overall survival. |
| NCT00347919 ↗ | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer | Completed | GlaxoSmithKline | Phase 2 | 2006-07-01 | This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the ErbB2 protein. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Pazopanib Hydrochloride
Condition Name
Clinical Trial Locations for Pazopanib Hydrochloride
Trials by Country
Clinical Trial Progress for Pazopanib Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Pazopanib Hydrochloride
Sponsor Name
